Skip to main content

Definity Side Effects

Generic name: perflutren

Medically reviewed by Drugs.com. Last updated on Feb 7, 2024.

Note: This document contains side effect information about perflutren. Some dosage forms listed on this page may not apply to the brand name Definity.

Applies to perflutren: intravenous suspension.

Warning

Intravenous route (Suspension)

Serious cardiopulmonary reactions, including fatalities, have occurred during or following perflutren-containing microsphere administration with the most serious reactions occurring within 30 minutes of administration. Assess all patients for any condition that precludes use of this product. Always have resuscitation equipment and trained personnel available.

Serious side effects of Definity

Along with its needed effects, perflutren (the active ingredient contained in Definity) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking perflutren:

Less common

Rare

Incidence not known

Other side effects of Definity

Some side effects of perflutren may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common

Rare

For Healthcare Professionals

Applies to perflutren: intravenous suspension.

General

The most frequently reported adverse reactions were headache, nausea and/or vomiting, warm sensation or flushing, dizziness, and back pain.[Ref]

Cardiovascular

Common (1% to 10%): Chest pain

Uncommon (0.1% to 1%): Abnormal ECGs, bradycardia, tachycardia, palpitation, hypertension, hypotension

Postmarketing reports: Fatal cardiac arrest, shock, syncope, symptomatic arrhythmias (atrial fibrillation, tachycardia, bradycardia, supraventricular tachycardia, ventricular fibrillation/tachycardia), hypertension, hypotension[Ref]

Serious but uncommon cardiopulmonary reactions, including fatalities, have been reported during or following administration of this medication. Most serious reactions occurred within 30 minutes of administration.

QTc prolongation of greater than 30 milliseconds occurred in 29% (64/221) of patients evaluated. Of these patients 72% (46/64) were further evaluated and 39% (18/46) were found to have cardiac rhythm changes. (Definity(R))[Ref]

Dermatologic

Common (1% to 10%): Flushing

Uncommon (0.1% to 1%): Pruritus, rash, erythematous rash, urticaria, increased sweating, dry skin[Ref]

Gastrointestinal

Common (1% to 10%): Nausea

Uncommon (0.1% to 1%): Dyspepsia, dry mouth, tongue disorder, abdominal pain, diarrhea, vomiting[Ref]

Musculoskeletal

Common (1% to 10%): Back pain

Uncommon (0.1% to 1%): Arthralgia[Ref]

Nervous system

Common (1% to 10%): Headache

Uncommon (0.1% to 1%): Leg cramps, hypertonia, vertigo, paresthesia, dizziness, taste perversion

Postmarketing Reports: Coma, loss of consciousness, convulsion, seizure, transient ischemic attack, agitation, tremor, vision blurred, dizziness, headache, fatigue[Ref]

Renal

Common (1% to 10%): Renal pain[Ref]

Genitourinary

Uncommon (0.1% to 1%): Albuminuria[Ref]

Hematologic

Uncommon (0.1% to 1%): Granulocytosis, leukocytosis, leukopenia, eosinophilia, hematoma[Ref]

Local

Uncommon (0.1% to 1%): Injection site reaction[Ref]

Ocular

Uncommon (0.1% to 1%): Conjunctivitis, abnormal vision[Ref]

Other

Uncommon (0.1% to 1%): Decreased hearing[Ref]

Respiratory

Uncommon (0.1% to 1%): Coughing, hypoxia, pharyngitis, rhinitis, dyspnea

Postmarketing reports: Fatal respiratory arrest, dyspnea, hypoxia, respiratory distress, stridor, wheezing[Ref]

Hypersensitivity

Postmarketing reports: Anaphylactic/anaphylactoid reactions[Ref]

Postmarketing reports of anaphylactic/anaphylactoid reactions have included: anaphylactic shock, hypersensitivity, bronchospasm, throat tightness, angioedema, edema (pharyngeal, palatal, mouth, peripheral, localized), swelling (face, eye, lip, tongue, upper airway), facial hypoesthesia, rash, urticaria, pruritus, flushing, and erythema.[Ref]

References

1. Cerner Multum, Inc. "Australian Product Information."

2. (2015) "Product Information. Definity (perflutren)." Lantheus Medical Imaging Inc

3. (2015) "Product Information. Optison (perflutren)." Mallinckrodt Medical Inc

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.